On August 1st, 2012, I joined the open seminar organized by Global Health Leadership Program (GHLP), the University of Tokyo.
The speaker is Dr. Ryo Kubota, M.D., Ph.D., Chairman, President & CEO of Acucela, Inc. The title of seminar is Drug development and innovations driven by bio ventures in the United States.
He described about how to introduce new molecule to the market and innovate as new drug.
FDA or U.S. Food and Drug Administration is the institute that has knowledge of all drugs from overall companies even confidential information, so it is good that all the drug companies let FDA checks the new products or experimental results before coming our to the market.
Process from discover to commercialization
When is the best time to start the drug company? Development phase should be the best time since we have done some amount of experiment until the risk already reduced. However, for him, he started since the beginning period.
There is difference between in Japan and US since Japanese people require quite high level of safety.
The cost of new drugs
The cost of new drugs increase every year. Currently, 2.7 Billion US Dollar is the fundamental cost to create one new drug development. It is capital intensive industry.
Current US health care costs exceed 17% GDP, while Japan is 8.5% GDP (That’s why we cannot see many new drugs come in Japanese market). However, the life expectation is better, so it means other factors that result this outcome in Japan is better than US.
Deep pile
The idea of deep pile shows that in case the drug company failed from one molecule, the company still can operate with other parallel molecule research.
Acucela
"The more diversity you are, the more idea you have", Dr. Kobuta explained that he tries to have multi nationality employees in his company because he believes that when we have any problems, people from difference places have different idea to solve the problem.
Drug development and innovations driven by bio ventures in the United States
No comments:
Post a Comment